Novel target identified for fragile X-linked autism
medwireNews: Researchers have elucidated a novel mechanism through which fragile X syndrome may contribute to behavioural symptoms of autism and identified a potential therapeutic target.
Using a mouse model, they found that knocking-out the gene encoding fragile X mental retardation protein caused the disruption of a special type of synaptic transmission that is dependent on an endocannabinoid factor.
Crucially, pharmacologic enhancement of this endocannabinoid restored some of the behavioral abnormalities of the knock-out mice, including impaired performance in a maze test.
"What we hope is to one day increase the ability of people with fragile X syndrome to socialize and engage in normal cognitive functions," said study co-author Daniele Piomelli (University of California, Irvine, USA) in a press statement.
Fragile X syndrome, the most frequently known genetic cause of autism, is characterized by a series of physical, cognitive, and emotional symptoms that include social deficits and a diminished ability to learn. Fragile X syndrome is due to the mutation of a single gene, called FMR1, which encodes the fragile X mental retardation protein.
In the current study, Piomelli and colleagues performed a raft of immunochemical assays on brain tissue taken from double knockout fmr1 - / - mice and wild-type mice.
They found that, in the mutant mice, the synapses of the ventral striatum and prefrontal cortex showed a disruption in a type of glutamate-dependent long-term depression (LTD).
Such LTD is a result of a reduction in the excitability of neuronal synapses, lasting hours or longer, and is a vital aspect of synaptic plasticity.
They subsequently found that this LTD is initiated by the endocannabinoid neurotransmitter, 2-arachidonoyl-sn-glycerol (2-AG), which acts in a retrograde fashion - by diffusing from the postsynaptic cleft to the presynaptic cleft -the opposite direction to classic neurotransmission.
However, in fmr1 - / - mutant mice, 2-AG appears to be degraded enzymatically, particularly by monoacylglycerol lipase, thereby disrupting LTD.
Notably, when the researchers treated mice with a pharmacologic inhibitor of MGL they saw dramatic behavioral improvements in maze tests measuring anxiety and open-space acceptance.
"The results identify the endocannabinoid signalosome as a molecular substrate for fragile X syndrome, which might be targeted by therapy," Piomelli et al comment in Nature Communications.
medwireNews (www.medwire-news.md) is an independent clinical news service provided by Springer Healthcare Limited. © Springer Healthcare Ltd; 2012
By Andrew Czyzewski, medwireNews Reporter